Invasive fungal infections: managing the continuum of risk in HCT patients. (August 2017)

• Record Type: Journal Article
• Authors: Duarte, Rafael F; Lyon, Sue
• Is Part Of: Future microbiology. Volume 12:Number 10(2017)
• Page Start: 843
• Page End: 846
• Publication Date: 2017-08
• Subjects: antifungal prophylaxis -- hematological malignancies -- invasive fungal infections; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb-2017-0092
• Languages: English
• ISSNs: 1746-0913

Abstract

43rd Annual Meeting of the EBMT, 26–29 March 2017, Marseille, France The European Society for Blood and Marrow Transplantation (EBMT) was established in 1974 to enable scientists and physicians to share their experience and develop studies in clinical bone marrow transplantation. Despite advances in treatment, invasive fungal infections (IFI), especially those caused by moulds such as Aspergillus, remain a leading cause of morbidity and mortality in patients with hematological malignancies. There is a continuum of risk of IFI during induction and consolidation therapy, and after hematopoietic cell transplantation. New, evidence-based approaches to the prevention, diagnosis and treatment of IFI were, therefore, of major interest to the over 5000 delegates from 85 countries attending the 43rd EBMT Annual Meeting (EBMT 2017).